What Is Custom DNA Oligonucleotide Synthesis?

Custom DNA oligonucleotide synthesis is the chemical process of building short, single-stranded DNA sequences—called oligonucleotides or “oligos”—in a controlled, laboratory setting. These synthetic DNA molecules are indispensable tools in modern molecular biology, genomics, diagnostics, and therapeutic development.

Whether you are designing primers for PCR amplification, probes for next-generation sequencing (NGS), CRISPR guide RNAs, or antisense oligonucleotides (ASOs) for gene silencing, understanding the key steps in custom oligonucleotide synthesis will help you make informed decisions about quality, yield, and application suitability.

Why Custom Oligonucleotide Synthesis Matters

Unlike natural DNA replication inside cells, solid-phase chemical synthesis allows scientists to create any arbitrary DNA sequence on demand. Key applications include:

•          PCR primers and probes for gene amplification and detection

•          Sequencing adapters for Illumina, Oxford Nanopore, and PacBio platforms

•          CRISPR-Cas9 guide RNAs (SgRNAs) for precision genome editing

•          Antisense oligonucleotides (ASOs) and siRNA for gene knockdown therapies

•          DNA templates for in vitro transcription

•          Molecular beacons and TaqMan probes for real-time qPCR

•          Synthetic gene blocks and gene assembly

The 8 Key Steps in Custom DNA Oligonucleotide Synthesis

Modern oligonucleotide synthesis follows solid-phase phosphoramidite chemistry, pioneered by Marvin Caruthers in the 1980s. The process is fully automated on synthesizer instruments and proceeds in the 3′ to 5′ direction—opposite to biological DNA replication.

The 8 Key Steps in Custom DNA Oligonucleotide Synthesis

Modern oligonucleotide synthesis follows solid-phase phosphoramidite chemistry, pioneered by Marvin Caruthers in the 1980s. The process is fully automated on synthesizer instruments and proceeds in the 3′ to 5′ direction—opposite to biological DNA replication.

Step 1: Sequence Design and Order Specification

The synthesis process begins before any chemistry—at the design stage. A well-designed oligonucleotide sequence is critical for downstream experimental success.

Key Considerations in Sequence Design:

  • GC content: Optimal range is 40–60% for balanced melting temperature (Tm)
  • Length: Typically 18–25 nucleotides for primers; up to 200+ nt for gene blocks
  • Secondary structures: Avoid self-complementarity and hairpin loops
  • 3′ end stability: Avoid repeated GC at 3′ end of PCR primers to reduce mispriming
  • Modifications: Specify fluorescent labels, biotinylation, phosphorylation, or LNA bases

Design tools such as Primer3, OligoCalc, IDT OligoAnalyzer, and NCBI Primer-BLAST are widely used to verify sequence specificity and thermodynamic parameters before ordering.

Step 2: Solid Support Loading — Anchoring the First Nucleotide

Synthesis occurs on a solid support—most commonly controlled pore glass (CPG) or polystyrene beads. The 3′-terminal nucleotide (the first base in the final sequence) is covalently attached to this support via a succinyl linker.

Solid Support Characteristics:

  • Pore size: Typically 500–2000 Å depending on oligo length
  • Loading: Measured in micromoles per gram (μmol/g)
  • Compatibility: Universal supports used for sequences ending in any base

The solid support is packed into a synthesis column, and all subsequent chemistry is performed in a flow-through fashion, allowing reagents to be added, reacted, and washed away in cycles.

Step 3: Deprotection (Detritylation) — Activating the Growing Chain

The 5′-OH of the support-bound nucleotide is initially protected by a dimethoxytrityl (DMT) group, which prevents unwanted reactions. Before each coupling cycle, this DMT group must be removed.

Detritylation Reaction:

  • Reagent: Trichloroacetic acid (TCA) or dichloroacetic acid (DCA) in dichloromethane
  • Result: Removal of DMT group, releasing a free reactive 5′-OH
  • Monitoring: The released orange-colored DMT cation is measured spectrophotometrically to calculate stepwise coupling efficiency (trityl-on monitoring)

This step is critical—incomplete detritylation leads to deletion sequences in the final product, reducing purity.

Step 4: Coupling — Adding the Next Nucleotide

This is the central step where the next phosphoramidite monomer is joined to the growing oligonucleotide chain. Each of the four DNA bases (A, T, G, C) is available as a protected phosphoramidite building block.

The Coupling Reaction Mechanism:

  1. Phosphoramidite monomer is dissolved in acetonitrile and activated by a weak acid tetrazole catalyst (e.g., 1H-tetrazole or 5-ethylthio-1H-tetrazole)
  2. The activated phosphoramidite reacts with the free 5′-OH of the support-bound nucleotide
  3. A phosphite triester linkage is formed between the new nucleotide and the chain

Coupling Efficiency: Modern automated synthesizers achieve >99% coupling efficiency per step. For a 20-mer oligo, this translates to a theoretical full-length yield of approximately 82% (0.99^20 ≈ 0.82).

Step 5: Capping — Blocking Uncoupled Sites

Despite high coupling efficiency, a small fraction (~0.5–1%) of growing chains fail to couple with the new nucleotide. If left unreacted, these truncated chains would continue growing in subsequent cycles, producing deletion sequences that are difficult to remove later.

Capping Solution:

  • Reagent A: Acetic anhydride in THF/pyridine
  • Reagent B: N-methylimidazole in THF
  • Result: Unreacted 5′-OH groups are acetylated, permanently blocking them from further chain elongation

Capping ensures that deletion sequences remain short (n-1, n-2) and are easier to separate during purification. This step dramatically improves the purity of the final product.

Step 6: Oxidation — Stabilizing the Phosphate Backbone

After coupling, the newly formed phosphite triester linkage is unstable under the acidic conditions used in detritylation. Oxidation converts this into a stable phosphotriester.

Oxidation Details:

  • Reagent: Iodine (I₂) in water/pyridine/THF
  • Result: Phosphite triester → phosphate triester (stable backbone linkage)
  • Alternative: Sulfurization with DDTT or Beaucage reagent to create phosphorothioate (PS) backbone—used in therapeutic antisense oligonucleotides for nuclease resistance

Phosphorothioate backbone modifications (S replacing O in the backbone) are a key chemical modification used in FDA-approved antisense drugs such as Nusinersen (Spinraza) and Inotersen.

Step 7: Cleavage and Deprotection — Releasing the Oligonucleotide

After the final synthesis cycle, the completed oligonucleotide must be cleaved from the solid support and all protecting groups must be removed.

Cleavage from Solid Support:

  • Standard protocol: Concentrated ammonium hydroxide (NH₄OH) at 55°C for 8–16 hours
  • Fast deprotection: AMA (ammonium hydroxide/methylamine) mixture reduces time to 10 minutes
  • RNA synthesis: Requires additional 2′-OH deprotection step (typically using TBAF or TEA·3HF)

What Gets Removed:

  • Succinyl linker connecting oligo to solid support

  • Cyanoethyl groups protecting the phosphate backbone
  • Base-protecting groups: Benzoyl (Bz) on A and C; isobutyryl (iBu) or PAC on G

The crude oligonucleotide solution is then evaporated under vacuum to yield a dry pellet ready for purification.

Step 8: Purification — Achieving Final Oligo Purity

The crude synthesis mixture contains the desired full-length product plus failure sequences (n-1, n-2 deletions), unreacted monomers, and protecting group fragments. Purification is essential for research-grade and especially therapeutic-grade applications.

Common Purification Methods:

A) Desalting / Size-Exclusion

  • Method: Spin column or gel filtration (NAP columns, Sephadex G-25)
  • Removes: Small molecules, salts, short oligomers
  • Best for: Oligos >15 nt where modest purity is acceptable
  • Typical purity: ~70–80% full-length product

B) Reverse-Phase HPLC (RP-HPLC)

  • Method: C18 column with acetonitrile/TEAA gradient
  • Removes: Failure sequences, n-1 deletions
  • Best for: Standard research primers and probes, modified oligos
  • Typical purity: >90% full-length product
  • DMT-on synthesis preferred: Final DMT group retained to improve separation

C) Polyacrylamide Gel Electrophoresis (PAGE)

  • Method: Denaturing PAGE (7–15% polyacrylamide, 7M urea)
  • Best for: Long oligonucleotides (>50 nt), CRISPR gRNAs, gene blocks
  • Typical purity: >95% full-length product
  • Limitation: Lower recovery; more labor-intensive

D) Ion-Exchange HPLC (IEX-HPLC)

  • Method: Anion-exchange column separating by charge (sequence length)
  • Best for: Therapeutic-grade ASOs, ultra-pure oligos
  • Typical purity: >98%, suitable for GMP manufacturing

Quality Control in Oligonucleotide Synthesis

After purification, rigorous quality control (QC) ensures the final product meets specifications. Standard QC methods include:

1. Mass Spectrometry (ESI-MS or MALDI-TOF)

Mass spectrometry is the gold standard for confirming oligonucleotide identity. The measured molecular mass is compared to the theoretical mass of the desired sequence, detecting deletions, insertions, or incomplete deprotection.

2. UV Absorbance (OD Measurement)

Quantification is performed by measuring UV absorbance at 260 nm (A260). The concentration is calculated using the Beer-Lambert law and the sequence-specific extinction coefficient. Results are reported in OD units, nmol, or micrograms.

3. Capillary Electrophoresis (CE)

CE provides high-resolution separation of oligonucleotides by length and charge, enabling accurate purity assessment and detection of n-1 failure sequences. Required for pharmaceutical-grade oligos under ICH Q2 guidelines.

4. Endotoxin Testing

For in vivo and therapeutic applications, endotoxin levels must be below 1 EU/mg (LAL assay). GMP synthesis facilities include endotoxin testing as a standard release criterion.

Common Chemical Modifications in Custom Oligo Synthesis

One of the greatest advantages of solid-phase synthesis is the ability to incorporate a wide variety of chemical modifications that expand functionality:

Modification Type

Examples

Application

Fluorescent labels

FAM, HEX, Cy3, Cy5, ROX, TAMRA

qPCR probes, FISH, single-molecule imaging

Backbone modifications

Phosphorothioate (PS), Boranophosphate

Therapeutic ASOs, nuclease resistance

Sugar modifications

2′-OMe, 2′-F, LNA, MOE

siRNA, gapmer ASOs, RNA therapeutics

5′ & 3′ end modifications

Biotin, thiol, amino, azide

Conjugation, immobilization, click chemistry

Base modifications

5-methylcytosine, inosine, dU

Epigenetic studies, universal bases

Quenchers

BHQ1, BHQ2, DABCYL, ZEN

TaqMan probes, molecular beacons

Synthesis Scale, Yield, and Delivery Format

Custom oligos are synthesized at various scales depending on application requirements:

Synthesis Scales:

  • 25 nmol: Standard research scale; suitable for most PCR and cloning applications
  • 100–200 nmol: Higher yield; preferred for sequencing adapters and diagnostic probes
  • 1–10 μmol: Scale-up for high-throughput applications, library preparation
  • GMP kilogram scale: For clinical and commercial therapeutic oligo manufacturing

Delivery Formats:

  • Dry (lyophilized) pellet: Most stable for long-term storage at -20°C
  • Aqueous solution: Resuspended in water or TE buffer; convenient but less stable
  • Normalized plates: 96-well or 384-well plates with standardized concentrations

Conclusion

Custom DNA oligonucleotide synthesis is a precisely engineered, multi-step chemical process that enables the on-demand creation of any desired DNA sequence. From solid support loading and phosphoramidite coupling to purification and quality control, each step plays a critical role in determining the purity, yield, and reliability of the final product.

Understanding these steps empowers researchers to make better decisions when ordering oligos—selecting the right synthesis scale, purification method, and chemical modifications for their specific application. As the fields of genomics, synthetic biology, and RNA therapeutics continue to advance, custom oligonucleotide synthesis will remain a cornerstone technology driving scientific discovery and medical innovation.

Frequently Asked Questions (FAQ) — SEO-Rich Content

Q: How long does custom oligonucleotide synthesis take?

Standard research oligos (18–25 nt, desalted or HPLC purified) are typically synthesized and shipped within 24–72 hours by commercial providers. Long oligos (>80 nt), heavily modified sequences, or PAGE-purified oligos may require 5–10 business days.

Q: What is the maximum length for custom oligo synthesis?

Standard solid-phase synthesis reliably produces oligos up to 100–120 nucleotides with acceptable purity. Longer sequences (up to 200+ nt) are achievable with specialized protocols, enhanced purification, and error correction. For gene-length sequences, overlapping oligos are assembled via Gibson Assembly or PCR-based gene synthesis methods.

Q: What purity level do I need for my application?

Desalted oligos are sufficient for most PCR amplification applications. HPLC purification (>90%) is recommended for sequencing, cloning, and functional assays. PAGE purification (>95%) is preferred for CRISPR applications, therapeutic studies, and single-molecule experiments. GMP-grade oligos (>98%, with full analytical documentation) are required for clinical use.

Q: What causes oligo synthesis failures or low yields?

Common causes include: repetitive sequences (poly-G, poly-A tracts), high GC content (>70%), long oligo length without yield optimization, aggressive chemical modifications at multiple positions, and secondary structure formation during synthesis. Experienced synthesis teams use modified protocols and protected monomers to mitigate these issues.

Q: How should I store oligonucleotides?

Dry (lyophilized) oligos are stable at -20°C for several years. Reconstituted oligos in water or TE buffer should be stored at -20°C in single-use aliquots to minimize freeze-thaw degradation. Avoid repeated freeze-thaw cycles. Modified oligos containing fluorescent dyes should be protected from light.

Q: What is the difference between RNA and DNA oligonucleotide synthesis?

RNA oligonucleotide synthesis follows the same phosphoramidite chemistry but uses ribonucleoside phosphoramidites with a 2′-O-TOM or 2′-O-silyl protecting group to prevent side reactions. RNA is more chemically labile than DNA and requires additional deprotection steps. RNA oligos are also more susceptible to RNase degradation, requiring RNase-free handling throughout.

References & Further Reading

  • Caruthers, M.H. (1985). Gene synthesis machines: DNA chemistry and its uses. Science, 230(4723), 281-285.
  • Beaucage, S.L. & Iyer, R.P. (1992). Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron, 48(12), 2223-2311.
  • ICH Q2(R1) Guideline on Validation of Analytical Procedures, 2005.
  • Crooke, S.T. et al. (2021). Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery, 20(6), 427-453.
  • IDT (Integrated DNA Technologies) — Oligonucleotide Synthesis Technical Guide, 2024
Order Now